BR112022003498A2 - Peptídeos recombinantes do tipo elastina imunotolerantes e métodos de uso - Google Patents
Peptídeos recombinantes do tipo elastina imunotolerantes e métodos de usoInfo
- Publication number
- BR112022003498A2 BR112022003498A2 BR112022003498A BR112022003498A BR112022003498A2 BR 112022003498 A2 BR112022003498 A2 BR 112022003498A2 BR 112022003498 A BR112022003498 A BR 112022003498A BR 112022003498 A BR112022003498 A BR 112022003498A BR 112022003498 A2 BR112022003498 A2 BR 112022003498A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- immunotolerants
- type peptides
- recombinant
- recombinant polypeptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962890936P | 2019-08-23 | 2019-08-23 | |
| PCT/US2020/040230 WO2021040881A1 (en) | 2019-08-23 | 2020-06-30 | Immune tolerant elastin-like recombinant peptides and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022003498A2 true BR112022003498A2 (pt) | 2022-08-16 |
Family
ID=74683687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022003498A BR112022003498A2 (pt) | 2019-08-23 | 2020-06-30 | Peptídeos recombinantes do tipo elastina imunotolerantes e métodos de uso |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220280615A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4017541A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022546384A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220103916A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114667160A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022003498A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3149274A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290839A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022002293A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021040881A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113444182B (zh) * | 2021-06-22 | 2022-07-19 | 四川大学华西医院 | 一种靶向递送IgG类抗体的融合蛋白载体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006110292A2 (en) * | 2005-03-25 | 2006-10-19 | The Regents Of The University Of California | Temperature-triggered immobilization and purification of antibodies |
| EP2758436B1 (en) * | 2011-09-23 | 2019-06-12 | Universität Stuttgart | Serum half-life extension using immunoglobulin binding domains |
| WO2016196249A1 (en) * | 2015-05-29 | 2016-12-08 | University Of Utah Research Foundation | Immune tolerant and non-immune tolerant elastin-like recombinant peptides and methods of use |
| WO2019071150A1 (en) * | 2017-10-06 | 2019-04-11 | University Of Utah Research Foundation | FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE |
| WO2019144309A1 (en) * | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine Fusion Proteins |
-
2020
- 2020-06-30 BR BR112022003498A patent/BR112022003498A2/pt unknown
- 2020-06-30 US US17/637,639 patent/US20220280615A1/en not_active Abandoned
- 2020-06-30 JP JP2022512869A patent/JP2022546384A/ja not_active Ceased
- 2020-06-30 EP EP20856151.4A patent/EP4017541A4/en not_active Withdrawn
- 2020-06-30 MX MX2022002293A patent/MX2022002293A/es unknown
- 2020-06-30 CN CN202080074005.2A patent/CN114667160A/zh active Pending
- 2020-06-30 WO PCT/US2020/040230 patent/WO2021040881A1/en not_active Ceased
- 2020-06-30 KR KR1020227009130A patent/KR20220103916A/ko not_active Ceased
- 2020-06-30 CA CA3149274A patent/CA3149274A1/en active Pending
-
2022
- 2022-02-23 IL IL290839A patent/IL290839A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220280615A1 (en) | 2022-09-08 |
| KR20220103916A (ko) | 2022-07-25 |
| EP4017541A4 (en) | 2023-08-23 |
| MX2022002293A (es) | 2022-06-02 |
| CA3149274A1 (en) | 2021-03-04 |
| IL290839A (en) | 2022-04-01 |
| CN114667160A (zh) | 2022-06-24 |
| WO2021040881A1 (en) | 2021-03-04 |
| EP4017541A1 (en) | 2022-06-29 |
| JP2022546384A (ja) | 2022-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992765A1 (ru) | Белки на основе антител с привитым цитокином и способы их применения в лечении рака | |
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| MX2023014059A (es) | Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante. | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| AR117728A1 (es) | Moléculas superagonistas de unión al antígeno cd28 con diana tumoral | |
| MX383614B (es) | Proteinas de union triespecificas y metodos de uso. | |
| BR112021019471A2 (pt) | Composições imunoterapêuticas e uso das mesmas | |
| MX2021014601A (es) | Proteinas recombinantes de union a fap y su uso. | |
| EA202091754A1 (ru) | Пептиды и комбинации пептидов неканонического происхождения для применения в иммунотерапии различных видов рака | |
| EA201791925A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| EA201992664A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака | |
| CL2019003408A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| WO2021222150A3 (en) | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications | |
| JP2015533376A5 (cg-RX-API-DMAC7.html) | ||
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| CL2020003292A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
| FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
| MX2020009550A (es) | Proteinas de union a antigeno antagonistas. | |
| BR112021022106A2 (pt) | Rna terapêutico para câncer de ovário | |
| MX2023006773A (es) | Composiciones de agentes de union a antigenos de guanilato ciclasa c (gcc) y metodos de uso de estos. | |
| EA201991444A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака | |
| BR112022007203A2 (pt) | Compostos imunogênicos para tratamento de câncer adrenal | |
| ZA202403355B (en) | Single domain antibodies binding to tetanus neurotoxin | |
| RU2019113989A (ru) | Лекарственное средство | |
| MX2024012582A (es) | Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |